The dialysis market has for decades been sustained by high rates of obesity and diabetes, which contribute to kidney damage, but GLP-1 drugs have shown to dramatically improve both conditions.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/j0NkCv8
via
DaVita sees limited impact from Ozempic's kidney trial success
October 13, 2023
0
Tags
-min.png)